Efficacy of drug in cough and cold

Efficacy of Habe-e-Gul-e-Pista in the secondary prevention of Surfa-e-tar among patients attending NIUM hospital, Bangalore - NIL

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/01/078917

Enrollment

Registered

2025-01-17

Start date

Unknown

Completion date

Unknown

Last updated

2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J40-J47- Chronic lower respiratory diseases

Interventions

Intervention1: Unani formulation of Hab-e-Gul-e-Pista: 150mg of Hab-e-Gul-e-Pista will be given orally twice a day for 15 days Control Intervention1: Not Applicable: Not Applicable

Eligibility

Inclusion criteria

Inclusion criteria: Patients of any gender. Age 18-60 years. Patients who have agreed to sign the informed consent form and follow up the protocol

Exclusion criteria

Exclusion criteria: Age below 18 and above 60 years. Known case of Malignancy. Severe systemic diseases. Pregnant and lactating women. Unstable Patients Bedridden Patients Mentally retarded Patients Seriously ill patients.

Design outcomes

Primary

Measure	Time frame
Improvement or any changes in clinical condition of surfa-e-tar.Timepoint: Intervention Period 15 days Enrollment Period 1 year	—

Secondary

Measure	Time frame
Not ApplicableTimepoint: Not Applicable	—

Countries

India

Contacts

Public ContactSaima Shafi

National Institute of Unani Medicine

arish_sherwani@yahoo.co.in9448794691

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026